German- based SynenTec has entered into a definitive agreement to acquire Roche's Cellavista business.
The acquisition will enable Roche to focus its business, and guarantee future optimal support and development of the technology for its customers.
Under the agreement, SynenTec will distribute Cellavista Systems as well as provide application support and services.
The Cellavista imaging system, which is designed for noninvasively measuring cell expansion, utilizes brightfield and fluorescence detection with multiwell plates, chamber slides or RoboFlasks, for various cellular applications including cell line development, cellular research and drug discovery.
Roche Applied Science head Dan Zabrowski said, "It is very important that we ensure uninterrupted support for our customers."
SynenTec CEO Matthias Pirsch said, "This acquisition adds significant value for Cellavista customers by enabling them to directly discuss their requirements and needs with the developer of the system."
